Determinants of Diabetes Remission After Gastric Bypass Surgery

EARLY_PHASE1CompletedINTERVENTIONAL
Enrollment

25

Participants

Timeline

Start Date

October 31, 2014

Primary Completion Date

August 31, 2017

Study Completion Date

July 31, 2019

Conditions
Type 2 Diabetes Mellitus
Interventions
DRUG

Exendin9

Dosed at 600 pmol/kg/min for 210 minutes.

Trial Locations (1)

10032

New York Obesity Research Center, Columbia University, New York

All Listed Sponsors
collaborator

National Institutes of Health (NIH)

NIH

collaborator

National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)

NIH

lead

Blandine Laferrere

OTHER

NCT02287285 - Determinants of Diabetes Remission After Gastric Bypass Surgery | Biotech Hunter | Biotech Hunter